YoungHeartValve was founded in 2020 following years of academic research that revealed a clear clinical gap in structural heart therapy. The founding team recognized a fundamental challenge in modern heart valve replacement: current valve technologies force a difficult trade-off. Mechanical valves offer durability but require invasive open-heart surgery and lifelong anticoagulation therapy, while tissue-based valves avoid anticoagulation but often deteriorate over time.
The company emerged from more than a decade of collaborative research conducted by cardiovascular biomechanical engineer Dr. Lakshmi Prasad Dasi and biomaterials scientist Dr. Susan James. Their work focused on the development of advanced polymeric materials capable of replicating the function of natural heart valve leaflets while overcoming the limitations of existing valve technologies.
A defining moment came during a six-month preclinical sheep study evaluating early valve prototypes. Both devices demonstrated strong performance, showing no evidence of thrombosis or calcification, two complications commonly observed in tissue-based valves. The results suggested that a polymeric approach could represent a meaningful advance in both valve durability and patient safety. These findings convinced the research team that the technology should move beyond the laboratory and toward clinical translation.
Following these results, the team filed a series of foundational patents establishing the core YoungHeartValve platform. Dr. James developed the polymeric leaflet biomaterial, while Dr. Dasi designed the stent-valve architecture and hemodynamic system that support the device’s performance. Together, these innovations formed the technological foundation of the company.
YoungHeartValve’s scientific roots trace back to NIH-funded research conducted across Colorado State University, The Ohio State University, and Georgia Tech. Dr. Dasi’s work in cardiovascular biomechanics and predictive modeling has focused on improving treatment planning for structural heart disease. He previously founded DASI Simulations, a company that developed patient-specific computational modeling tools to support clinical decision-making in cardiology.
Dr. James brings more than three decades of experience in the development of polymeric implant technologies. Earlier in her career, she helped translate advanced biomaterials into commercially successful orthopedic devices through the company BioPoly, providing valuable expertise in moving polymer-based innovations from laboratory research into clinical application.
